⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562167 | 1.00 | — | — | |
| SCHEMBL7817936 | 1.00 | — | — | |
| SCHEMBL2570696 | 0.72 | — | — | |
| SCHEMBL2570694 | 0.72 | — | — | |
| SCHEMBL2570691 | 0.72 | — | — | |
| SCHEMBL7595786 | 0.71 | — | — | |
| SCHEMBL2490679 | 0.69 | — | — | |
| SCHEMBL2490680 | 0.69 | — | — | |
| SCHEMBL8221750 | 0.69 | — | — | |
| SCHEMBL16174467 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-4041231-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020025574-A1 | PROCESS FOR THE PREPARATION OF 6-(HALOALKYL)-2-HALO-5-ACYLPYRIDINES AND INTERMEDIATES FOR THIS PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-06 | — | — | WO | disclosed |
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| EP-2499124-B1 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-9018234-B2 | Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-2086969-B1 | 3-CYANO-5-THIAZAHETEROARYL-DIHYDROPYRIDINE AND THE USE THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20100240620-A1 | 3-Cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010094405-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-2086969-A1 | 3-CYANO-5-THIAZAHETEROARYL-DIHYDROPYRIDINE AND THE USE THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Schering Pharma AG (DE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1926727-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008034534-A1 | 3-CYANO-5-THIAZAHETEROARYL-DIHYDROPYRIDINE AND THE USE THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |